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A B S T R A C T
Anemia with consequent tissue hypoxia is common problem in cancer patients. Developed via various patophysiologi-
cal mechanisms, it has deleterious effect on quality of life and survival of patients with cancer. Recognition of symptoms
and timely initiation of treatment improve patients’ quality of life, as well as efficacy of oncological treatment. Red blood
cells transfusions are well known and efficient way of anemia correction. They are »golden standard« in treatment of
cancer-related anemia today, and are unavoidable in almost all patients with hemoglobin concentration below 80 g/L.
Newest therapy guidelines in developed countries, supported by recent literature, encourage use of recombinant human
erythropoietin (rHu-EPO), although detailed meta-analyses and prospective randomized clinical trials have shown that
rHu-EPO decreases the need for transfusions in only 9–45% patients with cancer, only if they have mild anemia. rHu-E-
PO increases incidence of thromboembolic events, and suspicion arises that it supports tumor cells growth and multipli-
cation. Therefore, it is necessary to define subgroups of patients which are best candidates for rHu-EPO therapy, to ac-
complish lower intensity of transfusion therapy.
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Introduction
Anemia in cancer patients has become significant cli-
nical problem during recent years. Increased efficiency of
cancer therapy results in better overall survival as well
as in prolonged survival of non-curable patients. Respec-
tively, quality of life of non-curable patients is becoming
more and more significant. Fatigue, one of most common
symptoms of metastatic cancer, is one of main issues re-
lated to quality of life, and probably most neglected in cli-
nical practice. Since anemia is most common cause of fa-
tigue, clinical trials have been conducted that correlated
anemia with quality of life and, later, anemia with overall
survival. Because of persistent problem of insufficient
blood supply, new medications have been developed (re-
combinant human erythropoietins, rHu-EPO) with pur-
pose to decrease number of blood transfusions.
Definition, etiology and consequences of anemia
in cancer patients
Anemia is defined as lowered hemoglobin concentra-
tion (in males below 140 g/L, in females below 120 g/L),
usually associated with low red blood cells (RBC) count
(in males <4,3  109/L, in females <3,86  109/L). Multi-
ple pathogenic mechanisms are responsible for develop-
ment of anemia in patients with cancer (Figure 1). It
usually presents as anemia of chronic disease, and in the
moment of cancer diagnosis is present in about 40–64%
of patients. Since myelosupressive effect of oncological
treatment modalities, its incidence during the treatment
increases up to 80%1.
Main molecular mechanisms of listed processes are
nonspecific activation of monocytes and consequent sec-
retion of proinflammatory cytokines (neopterin, inter-
pheron-gamma, tumor necrosis factor, and interleukin-6)
and Fas ligand (FASL) molecules. Apoptotic mechanisms
are triggered in erythroblasts by FASL and TNF, and pro-
cess is amplified by secretion of TNF from tumor cells.
Tissue hypoxia is main consequence of anemia and it
leads to changes in cell microenvironment. Cells switch
from aerobic to anaerobic metabolism, lactate production
is increased and, consequently, acidosis of cell microenvi-
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ronment develops. In normal cells apoptotic mechanisms
are triggered if hypoxia is prolonged, while malignant
phenotype promotion is started in the tumor tissue. Se-
lection of cells resistant to hostile microenvironment be-
gins and on the other hand oncological treatment modali-
ties are less efficient in hypoxic conditions – radiotherapy
due to lack of oxygen and reduction of free radicals pro-
duction, and chemotherapy due pharmacokinetics chan-
ges in lowered pH conditions. Apoptotic pathways are
modulated by sensors of hypoxia – HIF (hypoxia induc-
ible factors) 1 a and b. Normally, there is a dynamic bal-
ance of synthesis and degradation of HIF-1a in organism.
Oxygen and two-valent ions of iron are cofactors for pro-
lyl-hydroxilase activation, the enzyme which carries out
HIF-1a degradation, and in their absence the substrate
accumulates. HIF-1a accumulation activates transcrip-
tion mechanisms for erythropoietin synthesis in hemato-
poietic cells, whilst in other cells expressing HIF recep-
tors it activates anaerobic metabolism and apoptotic
mechanisms. Besides anaerobic metabolism and adapta-
tion of tumor cells to hostile microenvironment, tran-
scription mechanisms are activated as well, as follows:
for synthesis of vascular endothelial growth factor (VEGF)
which reflects in angiogenesis promotion, and for epider-
mal, insulin-like and transforming growth factors (EGF,
IGF-2 and TGF-b) with consequent promotion of tumor
cells growth and division. All the worse, this closes the vi-
cious circle of tumor hypoxia, clonal selection and malig-
nant disease progression in anemic cancer patients.
Severity of anemia
The most commonly used classifications of anemia
toxicity are by World Health Organization and by Natio-
nal Cancer Institute. Anemia is staged in four groups, ac-
cording to both (Table 1)2.
Anemia and Quality of Life
Anemia has detrimental effect on cancer patients’
quality of life. Main symptoms of anemia are fatigue, diz-
ziness, headache, pallor, dyspnea, tachycardia, palpita-
tions, depression, lowered mental capabilities and loss of
libido. Fatigue is most common symptom of metastatic
cancer, and is usually caused by anemia. The tumor’s
theft of nutrients, infection and disruption of normal
body processes also account for fatigue. In clinical prac-
tice 80% of oncologists overlook fatigue as main symptom
of anemia, and almost two thirds of physicians think that
pain is greater problem than fatigue. On the contrary,
two thirds of patients think that fatigue is greater prob-
lem than chronic malignant pain3. Incidence and severity
of anemia depend on several factors: type of tumor (ane-
mia is most common in patients with lung, gynecologic,
genitourinary tumors and lymphomas), stage of disease,
treatment modality (anemia is present in 63% of patients
treated by chemotherapy alone, 42% of patients treated

































Fig. 1. Causes of anemia in cancer patients. Mechanical (lowered RBC production due to tumor infiltration of bone marrow, and direct
lysis of red blood cells during hematogenic dissemination of malignant cells), blood loss (hemorrhage from tumor itself), and activation
of immune system (hemophagocytosis; synthesis of antibodies to erythroid cells with consequential autoimmune hemolytic anemia or
red blood cells aplasia in bone marrow; and modulation of cytokine expression with consequential humoral and cellular suppression of
erythropoiesis and erythropoietin secretion suppression in kidneys).
TABLE 1
STAGING OF ANEMIA SEVERITY
Severity of anemia WHO NCI
Grade 0 > 110 g/L WNL
Grade I (mild) 95–109 g/L 100 g/L – WNL
Grade II (moderate) 80–94 g/L 80–110 g/L
Grade III (severe) 65–79 g/L 65–79 g/L
Grade IV (life-threatening) < 65 g/L <65 g/L
WNL hemoglobin values are 120–160 g/L for women and 140–
180 g/L for men. Adapted from Groopman and Itri, Oxford Uni-
versity Press, 1999.
by chemo-radiotherapy, and in 19,5% of patients treated
by radiotherapy alone)4, patients age, and bone marrow
reserve.
Anemia and Survival (Impact on Efficacy
of Oncologic Treatment Modalities)
Anemia is independent prognostic factor of lower sur-
vival and lower efficacy of oncologic treatment. Relative
risk to death is about 60% higher in anemic cancer pa-
tients; 75% in patients with ovarian cancer, 67% in pa-
tients with lymphomas, in 47% in patients with prostate
cancer, and in 19% in patients with lung cancer5.
Anemia has negative effect on both radiotherapy and
chemotherapy efficiency. In hypoxic conditions quantity
of oxygen in irradiated volume is lowered, and since
hypoxic tumor cells are radioresistant, higher radiation
dose is necessary for tumor cell eradication. Therefore,
radiosenzitizers (medications which increase binding of
oxygen to hemoglobin) increase radiotherapy efficiency
as well as correction of anemia (Figure 2). Optimal hemog-
lobin level for best effect of radiotherapy is 120–140 g/L6.
Hypoxia causes switch of cancer cells to anaerobic me-
tabolism, and acidosis of cellular microenvironment de-
velops. Pharmacokinetic changes lead to lack of efficacy
of certain cytotoxic drugs. Dependency of cyclophospha-
mide, carboplatin and doxorubicin effect on cancer cell
killing and tumor oxygenation has been proven in vitro
and in vivo7. Having in mind that anemia is more com-
mon in certain types of tumors, especially ones sensitive
to cytotoxic chemotherapy since the treatment is usually
more intensive, additional concern should be attributed
to this issue. Cumulative myelosupressive effect is usu-
ally fully expressed after fourth cycle of chemotherapy
(Figure 3).
Impact of anemia on efficiency of cancer therapy has
been tested in few clinical trials. Grogan et al. have
shown that 5-yr survival in patients with cervical cancer
treated by radiotherapy is 25% worse if average hemoglo-
bin level was below 120 g/L, and that it improves with
correction of anemia (Figure 4)8.
Bookemeyer and associates have proven 21% reduc-
tion in 5-yr overall survival (p<0,05) if average hemoglo-
bin level was below 105 g/L in 101 patients with »poor
prognosis« metastatic testicular cancer treated with
three cycles of PEI chemotherapy, followed by three cy-
cles of high dose PEI chemotherapy (Figure 5)9.
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Fig. 2. Dose-effect curve and relation to hypoxia and radiosenzi-
tizers.
Fig. 3. Cumulative myelosupressive effect of chemotherapy. Re-
printed by permission from Macmillon Publishers Ltd: Br J
Cancer 82 (2000) 93: Barrett-Lee PJ, Bailey NP, O’Brien MER,
Wager E. Large-scale UK audit of blood transfusion require-
ments and anaemia in patients receiving cytotoxic chemotherapy.
Copyright © 2000.
Fig. 4. Dependency of survival to hemoglobin concentration in
patients with cervical cancer treated with radiotherapy. 475 pa-
tients have been stratified into four groups: patients with low ba-
seline hemoglobin level whose hemoglobin remained low during
the treatment (L–L), patients with high baseline hemoglobin
whose hemoglobin dropped below 120 g/L during the treatment
(H–L), patients with high baseline hemoglobin level whose hemo-
globin remained high (H–H), and patients with low baseline he-
moglobin whose hemoglobin concentration was corrected by
transfusions to value >120 g/L during the treatment (L–H). Pa-
tients with corrected hemoglobin level had survival similar to
patients with high baseline hemoglobin who remained >120 g/L,
while patients with fall in hemoglobin level below 120 g/L during
the treatment had similar survival with patients with low hemo-
globin whose hemoglobin remained low. Survival difference be-
tween the two groups was statistically significant (p<0,0002).
Adapted from Grogan M, et al. The importance of hemoglobin le-
vels during radiotherapy for carcinoma of the cervix, Cancer
1999;86:1528-1536, by permission of the publisher Wiley Inter-
Science, Copyright © 1999 American Cancer Society.
Transfusion Therapy in Cancer Patients
Scientific and therapeutical application of blood tran-
sfusions first started about one hundred years ago, when
Landsteiner revealed blood groups at the beginning of
twentieth century. Thanks to modern techniques of prep-
aration and storage, they can be stored before applica-
tion even ten years after blood collection. RBC transfu-
sions are common medical intervention; in United States,
about 4 million people receive blood transfusion every
year, mainly surgical patients (60–70%). Cancer patients
generally receive blood transfusions when hemoglobin
level drops to about 70–80 g/L, with higher cut off value
in patients with cardiac and pulmonary comorbidity, sin-
ce symptoms and signs of anemia are usually more inten-
sive. Estimates show that 33% of patients with cancer re-
ceive blood transfusion at least once, and about 16%
receive multiple RBC transfusions during the treat-
ment10. In clinical practice, anemia is treated in only 39%
of anemic cancer patients, in spite of deleterious effect of
anemia on quality of life. In Europe, 17% of patients are
treated by rHu-EPO, about 15% by RBC transfusions,
and about 9% by iron supplements11. Prompt effect in
anemia correction in practically every patient who recei-
ves it, as well as relatively low cost of treatment (about
208 US$ per patient during 4 cycles of chemotherapy),
are main advantages of transfusion therapy in cancer pa-
tients12.
Three main controversies remain in transfusion ther-
apy of cancer patients. Harmful immunomodulatory ef-
fect has never been proven in patients with cancer, while
risk of transmission of infectious diseases has been mini-
mized by modern techniques of detection and prepara-
tion of blood derivates. Certain risk of transfusional reac-
tions still remains, but with adequate caution they can
almost always be avoided.
Insufficient blood supply is the crucial problem in
transfusion therapy of cancer patients, especially in de-
veloped countries. Cancer patients are too numerous to
be adequately treated by transfusion therapy with cur-
rent blood supply. In clinical practice, this is usually
reflected through delaying transfusions until hemoglo-
bin level drops significantly.
Blood transfusions should be given on individual ba-
sis rather than predefined hemoglobin concentrations, to
treat acute anemia if crystalloid fluids have no effect on
correction of intravascular anemia, and to treat chronic
anemia if iron supplements or rHu-EPO have no effect.
In patients with cancer RBC transfusions should also be
given when there is not enough time to wait for (possible)
effect of rHu-EPO, i.e. when rapid malignant disease pro-
gression is expected.
Erythropoietin and Correction of Anemia
Erythropoietin is glycoprotein hormone produced
predominantly in kidney, and only to a minor degree in
liver13. Its production is regulated by hypoxia through
transcriptional factor HIF-1 and effect is mediated by re-
ceptor (EpoR) on erythroid progenitor cells in bone mar-
row stimulating their proliferation14. Recombinant hu-
man erythropoietin (rHu-EPO) has initially been used to
treat patients with chronic renal failure15 and in 1993
FDA approved its use in cancer patients. There are 3
commercially available products, epoetin alpha, epoetin
beta and darbopoetin.
Erythropoietin, blood transfusion
requirements and quality of life
It is unequivocal that rHu-EPO treatment can reduce
the need for blood transfusions in cancer patients and,
consequently, improve patients’ quality of life (QoL).
In randomized, placebo-controlled study by Littlewood
et al. epoetin alpha 150 to 300 IU/kg was administered to
the patients with solid or nonmyeloid hematological ma-
lignancies and hemoglobin levels below 105 g/L or grea-
ter than 105 g/L but 120 g/L or less, after hemoglobin de-
crease since start of chemotherapy16. In epoetin alpha
arm transfusions requirements were significantly lower
compared with placebo (24.7% vs. 39.5%, p=0,057) and
hemoglobin levels were significantly increased (22 g/L vs.
5 g/L, p<0.001).
Seidenfeld et al. have done a meta-analysis of the
early clinical trials with epoetin alpha by the year 200117.
Twenty-two trials were included. Epoetin alpha reduced
the percentage of patients transfused by 9% to 45% in pa-
tients with basal hemoglobin levels 100 g/L or lower, and
by 7% to 47% in patients with basal hemoglobin levels
between 100 g/L and 120 g/L. Odds ratio for transfusions
in epoetin treated arm compared with control arm was
0.45 (95%CI 0.33–0.62) in higher quality studies and 0.14
(95%CI 0.06–0.31) in lower quality studies. Overall 4.4
patients were treated with epoetin alpha to avoid one
blood transfusion.
In updated meta-analysis by Bohlius and al. treat-
ment with rHu-EPO reduced the transfusions require-
ments by 36% (RR 0.64, 95%CI 0.60–0.68), and achieved
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Fig. 5. Dependency of survival to hemoglobin concentration in
patients with testicular cancer treated with high dose PEI che-
motherapy. Reprinted by permission from Macmillon Publishers
Ltd: Br J Cancer 87 (2000) 1066:Boekemeyer C, et al. Treatme-
nt-induced anaemia and its potential clinical impact in patients
receiving sequential high dose chemotherapy for metastatic testi-
cular cancer, Copyright © 2002.
hematological response (defined as increase in hemoglo-
bin concentration by 20 g/L) significantly more often (RR
3.43,95%CI 3.07-3.84)18.
Meta-analysis of 40 clinical trials including 21378 pa-
tients, confirmed the mentioned results19. The odds ratio
for transfusions in studies of epoetin versus control was
0.44 (95% CI, 0.35–0.55) and of darbopoetin versus con-
trol 0.41 (95% CI, 0.31–0.55). There were no clinically re-
levant differences between epoetin and darbopoetin.
Littlewood et al. showed that epoetin treatment signi-
ficantly improved patients’ QoL compared with placebo
measured by LASA (linear analog scale assessment) and
FACT-An (Functional assessment of cancer therapy-ane-
mia subscale)4. Other randomized and nonrandomized
trials confirmed similar results20–26. Regarding darbopoe-
tin alpha and QoL, Vancteenkiste et al. showed no signifi-
cant improvement in FACT-An score in darbopoetin
group but 32% of patients in the treatment group had at
least 25% improvement in score compared to only 19% in
the placebo group (p=0.019)27. In another trial Hedenus
et al. demonstrated that patients treated with darbopoe-
tin alpha had significantly greater improvement in FA-
CT-An score compared with those given placebo28. Addi-
tional analysis of two community based trials of epoetin
beta showed that the largest QoL improvements for each
10g/L increment in hemoglobin level occurred when he-
moglobin increased from 110 to 120 g/L29.
Erythropoietin in cancer patients – pro et contra:
side-effects and overall survival
The most common side-effects of rHu-EPO treatment
are hypertension and thromboembolic events. The meta-
-analysis of 39 clinical trials including 6769 patients pro-
vided conclusive evidence that rHu-EPO treatment in-
crease the risk for thromboembolic events (RR 1.67,
95%CI 1.35–2.06)6.
Pure red cell aplasia and development of anti-erythro-
poietic antibodies described in patients with chronic re-
nal failure has not been observed in patients with can-
cer30.
Early trials showed better survival in rHu-EPO trea-
ted patients. In a nonrandomized study epoetin treated
patients undergoing neoadjuvant chemoradiotherapy
and resection for squamous cell carcinoma of the head
and neck have significantly better local control and sur-
vival compared with an untreated historical control
group31. A trend toward survival benefit was demonstra-
ted in randomized trial of patients receiving epoetin al-
pha and chemotherapy4. In patients with various pelvic
malignancies receiving radiotherapy treatment with
epoetin beta improved tumor control and survival32. Dar-
bopoetin alpha treatment was associated with prolonged
progression free survival in patients with small cell lung
cancer33. A meta-analysis by Bohlius and al. reported a
trend towards improved survival with epoetin34 although
a recent update showed a shift towards increased mortal-
ity HR 1.08 (95%CI 0.99–1.18)6. Most of the trials inclu-
ded in this meta-analysis were not designed to measure
overall and progression-free survival. Epoetin beta meta-
-analysis has not recorded any survival benefit but there
was significantly reduced risk of rapidly progressive dis-
ease (HR0.78; p=0.042)35. MARCH (Management of
Anemia under RadioChemotherapy in cervical cancer)
study investigated effect of epoetin beta compared with
supportive care on overall survival and progression-free
survival in anemic patients with cervical cancer receiving
radiochemotherapy36. There was no significant outcome
on overall (rR1.0, p=0.99) and progression-free survival
(RR 1.16, p=0.57). Similar results were demonstrated in
BRAVE (Breast Cancer-Anemia and the Value of Eryth-
ropoietin) study37. It was designed to determine is there a
survival benefit with epoetin beta treatment in patients
with metastatic breast cancer receiving anthracycline
and/or taxane-based chemotherapy.
In conclusion, most of the studies and meta-analyses
have not confirmed any positive or negative effect on sur-
vival in cancer patients receiving chemotherapy and/or
radiotherapy.
Recent results of 4 large randomized trials have rai-
sed the question of negative impact of rHu-EPO treat-
ment on survival and tumor progression in cancer pa-
tients.
Breast Cancer Erythropoietin trial (BEST) determi-
ned higher mortality rate in patients with metastatic
breast cancer treated with chemotherapy and epoetin al-
pha compared with chemotherapy alone38. This imbal-
ance in mortality occurred in first 4 months mostly due
disease progression (6% vs. 2.8%) or increase incidence of
thromboembolic complications (1% vs. 0.2%) in the epoe-
tin group. At 19 months there was a convergence of sur-
vival curves39. This study has several methodological lim-
itations that were confirmed by the authors themselves.
Patients in epoetin group have had more risk factors for
thromboembolic complications, more advanced disease
or poorer performance status at the beginning of the
trial. Meta-analysis of 8 randomized epoetin beta trials
failed to show increased mortality due to thromboembo-
lic complication (3.17 thromboembolic events yearly in
epoetin beta group compared with 3.36 yearly in control
group and 1.1% mortality in both groups)40. Neither the
meta-analysis by Apro and el. determined increased mor-
tality due to thromboembolic events in patients treated
with epoetin beta although there was increased incidence
of thrombosis, deep vein thrombosis and pulmonary em-
bolism (5.9% vs. 4.2%)23.
Henke et al. investigated epoetin beta treatment com-
pared with placebo in 351 patients with head and neck
cancer during radiotherapy41. Patients were given rela-
tively higher epoetin beta doses (300 IU/kg 3 times
weekly) and hemoglobin target levels were 140 g/L for
women and 150 g/L for men. Significantly worse survival
(relative risk of death 1.39, 95%CI 1.05–1.84, p=0.02)
and locoregional progression (RR 1.69, 95%CI 1.67–2.47;
p= 0.007) was determined in epoetin group. Patients in
treatment group experienced more hypertension, bleed-
ing, thrombosis and pulmonary embolism (11% vs. 5%)
and died more often due to cardiovascular incidents
S. Bad`ek et al.: Treatment of Cancer-Related Anemia, Coll. Antropol. 32 (2008) 2: 615–622
619
(5.5% vs. 3%). After 9 weeks of therapy hemoglobin level
of 15417 g/L was achieved, what is above physiological
concentration. Theoretically such high hemoglobin con-
centration could lead to increased blood viscosity and
thereby reduced tumor oxygenation42. Henke et al. have
also made an analysis that has shown that patients who
had erythropoietin receptors expressed on tumor cells
had poorer progression-free survival after rHu-EPO
treatment compared to placebo (adjusted relative risk
2,07; 95% CI, 1,27–3,36; p<0,01), while in patients who
received rHu-EPO treatment and were receptor-negative
there was no outcome impairment (adjusted relative risk
0,94; 95% CI, 0,47–1,90; p=0,86)43. Concerns have been
expressed regarding the specificity of EpoR C20 antibody
used because it has been clearly demonstrated that it
cross-reacts with heat shock protein–7044–46.
Randomized placebo controlled trial of epoetin alpha
in patients with non-small cell lung cancer (NSCLC) was
preliminary terminated on unplanned safety analysis
due to significant difference in overall survival favoring
placebo group (63 vs. 129 days; HR1.84; p=0.04)47. In-
creased mortality was consequence of thromboembolic
complications in patients treated with epoetin beta. Pri-
mary outcome of the trial was to verify QoL improve-
ment for patients with NSCLC unsuitable for curative
treatment and baseline hemoglobin levels less than 121
g/L.
DAHANCA 10 (Danish Head and Neck Cancer 10
trial) was terminated due to increased mortality of the
patients treated with darbopoetin alpha compared with
placebo (HR 1.25; 95%CI 1.04–1.51)48. Trial was desig-
ned to determine benefit of darbopoetin beta treatment
in head and neck cancer patients while not receiving any
chemotherapy and/or radiotherapy.
It is important to notice that patients in 2 studies
mentioned above were not treated following recommen-
ded ASCO guidelines since they received no cancer speci-
fic therapy.
Functional EpoR expression has been documented on
many nonhematopoietic cell types e.g. vascular endothe-
lial cells49, smooth muscle cells50, cardiac myocytes51,
neurons52, retinal photoreceptors53 and many others.
Erythropoietin is involved in diverse nonhematopoietic
biological functions such as angiogenesis and granula-
tion tissue formation54 or cellular proliferation55.
Expression of EpoR has been reported in many tumor
cell lines as well as primary cancers56. The question
arises regarding autocrine or paracrine erythropoietin
effect on tumor proliferation, apoptosis, angiogenesis
and possibly even radio or chemo sensibility.
Some in vitro or animal model studies suggest that
erythropoiesis-stimulating agents (ESA) may stimulate
tumor cell proliferation but others have failed to show
these effects57. Tumor regression was demonstrated fol-
lowing local injection of Epo antibodies58.
In human cervical cancer cells (HeLa) pretreated with
different doses of epoetin and than challenged with cis-
platin survival was dose dependent59. Same study also
demonstrated strong correlation between expression of
EpoR and bcl-2. However in another study lower doses of
epoetin had no effect on bcl-2 expression60. Decreased
sensitivity to cisplatin of cancer cell lines exposed to
epoetin was reported in two studies61,62 while in others
there was no such effect63 or pro-apoptotic effect was de-
termined64.
As mentioned before, EpoR has been identified in en-
dothelial cells33 and there is possibility of correlation be-
tween erythropoietin and angiogenesis. A study of tumor
cells demonstrated increased production of angiogenic
growth factor VEGF following treatment with high doses
of epoetin65 and inhibition of angiogenesis and decreased
tumor cell survival after treatment with EpoR antago-
nist66.
When evaluating preclinical studies, we have to consi-
der that doses of epoetin used are several times higher
than physiological doses or those achieved in patients
treated with rHu-EPO40.
In conclusion, rHu-EPO therapy plays a significant
role in lowering the need for blood transfusions, as well
as in improving of quality of life of patients with cancer.
It seems that rHu-EPO therapy has no negative but neit-
her has positive effect on overall survival and malignant
S. Bad`ek et al.: Treatment of Cancer-Related Anemia, Coll. Antropol. 32 (2008) 2: 615–622
620
TABLE 2
ADVERSE OUTCOMES ASSOCIATED WITH ERYTHROPOIETIN TREATMENT IN CANCER PATIENTS







Henke et al. Locally advanced
head and neck
cancer




Hazard ratio for local-regional
progression 1,69 (P 0,007);
hazard ratio for death 1,39 (p 0,02)




130 Survival at 12 mo. vs. placebo 70%
vs. 76% (p 0,01)
Wright et al. Metastatic NSCLC 70 Epoetin alfa
40000 U/wk
120–140 OS vs. placebo 63 vs. 129 days;






140–155 10% increase in local-regional
failure (p=0,01); trend toward
shorter survival (p=0,08)
NSCLC – non-small-cell lung cancer, OS – overall survival. Modyfied from Khuri FR, 2007.
disease progression while approved guidelines are fol-
lowed. Results of four mentioned clinical trials with neg-
ative impact on survival allow certain suspicion regard-
ing safety of rHu-EPO therapy, especially having in mind
contradictory results of preclinical trials exploring EpoR
role in tumor cells (Table 2).
Conclusion
Correction of anemia should be one of priorities when
treating patients with cancer, because of consequential
tumor hypoxia and progression of malignant disease.
Anemia reduces both quality of life and overall survival
of cancer patients as well as efficacy of both main oncolo-
gical treatment modalities – radiotherapy and chemothe-
rapy. Anemia is separate prognostic factor for survival in
patients with cancer.
Two main questions are to be answered by ongoing
clinical trials: when to start treating anemia, and which
target hemoglobin value to strive? According to currently
available data, hemoglobin concentration optimal for
maximum efficiency of oncological treatment is 120–130
g/L, and treatment of anemia should be started as soon
as hemoglobin level drops below 110 g/L, since best im-
provement in quality of life can be achieved.
Two main available modalities for treatment of ane-
mia are supportive therapy (blood transfusions) and re-
combinant human erythropoietins. Prophylactic applica-
tion of rHu-EPO is still under clinical evaluation, as well
as identification of patients optimal for erythropoietic
therapy. Question if erythropoietic agents are suitable
for patients with all types of cancer remains unanswered.
Predictive factors for erythropoietic therapy are probab-
ly going to be defined in near future.
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LIJE^ENJE ANEMIJE U ONKOLO[KIH BOLESNIKA
S A @ E T A K
Anemija s posljedi~nom tkivnom hipoksijom ~est je problem u onkolo{kih bolesnika. Nastaje razli~itim patofizio-
lo{kim mehanizmima i ima lo{ u~inak na kvalitetu `ivota i pre`ivljenje bolesnika s malignim bolestima. Prepoznava-
njem simptoma i pravovremenim zapo~injanjem lije~enja pobolj{avamo kvalitetu `ivota bolesnika, kao i u~inkovitost
onkolo{kog lije~enja. Transfuzije eritrocita dobro su poznat i u~inkovit na~in korekcije anemije. Danas predstavljaju
»zlatni standard« lije~enja anemije uzrokovane malignom bole{}u i neizbje`ne su u gotovo svih bolesnika s koncentraci-
jom hemoglobina ispod 80 g/L. Najnovije terapijske smjernice u razvijenim zemljama, sukladno novijim znanstvenim
spoznajama, ohrabruju uporabu rekombinantnog humanog eritropoetina (rHu-EPO), iako su detaljnije meta-analize i
prospektivna randomizirana istra`ivanja pokazala kako rHu-EPO smanjuje potrebu za transfuzijama u samo 9–45%
onkolo{kih bolesnika, i to samo ukoliko imaju blagu anemiju. rHu-EPO pove}ava u~estalost tromboembolijskih incide-
nata, a postavljena je i sumnja o promotivnom u~inku na rast i razmno`avanje tumorskih stanica. Potrebno je jasno de-
finirati skupine bolesnika koji su najpogodniji kandidati za lije~enje s rHu-EPO, a s ciljem smanjenja intenziteta tran-
sfuzijskog lije~enja.
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